ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS | Zendy

Svetlana Vorotnikova | Zendy; Е А Пигарова | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS

Author(s) -

Svetlana Vorotnikova,

Е А Пигарова

Publication year - 2016

Publication title -

osteoporosis and bone diseases

Language(s) - English

Resource type - Journals

eISSN - 2311-0716

pISSN - 2072-2680

DOI - 10.14341/osteo2016323-27

Subject(s) - zoledronic acid , osteogenesis imperfecta , medicine , osteoporosis , bone density conservation agents , primary hyperparathyroidism , clinical trial , bone disease , bisphosphonate , oncology , dentistry , bone density , pathology

The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research